Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UCB Inks Buyback-Option Deal With Wilex For Oncology Lineup

This article was originally published in The Pink Sheet Daily

Executive Summary

Sharing costs and risk could help ease UCB’s recent woes with Cimzia, Neupro.

You may also be interested in...



Deal Watch: Genentech Pays Big For Seragon’s Early Assets

Genentech pays $725 million upfront for San Diego oncology firm Seragon, and Bluebird adds gene-editing and cell-signaling capabilities by acquiring Precision Genomic Engineering. It was a deal-heavy week ahead of the July 4th Holiday.

UCB’s New Strategy Takes SHAPE As GSK Buys Out Emerging Markets

For about $670 million, GSK acquires UCB drugs and infrastructure in several dozen non-BRIC markets.

UCB’s New Strategy Takes SHAPE As GSK Buys Out Emerging Markets

For about $670 million, GSK acquires UCB drugs and infrastructure in several dozen non-BRIC markets.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel